We recently demonstrated that LiCl, a GSK-3β inhibitor, induces mesenchymal-to-epithelial transition (MET) in vitro, suggesting that LiCl and GSK-3β could represent, respectively, interesting drug and target for CRC therapy (55). Here, GSK3B is linked to colorectal carcinoma.